- 新型肺炎
- ドイツ
- 新型コロナウイルス感染症
- 厚労省
- マスク
- 発表
- 期待
- ぜんそく
- 令和
- 作業
「レムデシビル」の写真・グラフィックス・映像
- 提供元
- 日付
- 種類
- 向き
- カテゴリ
- 色
- 提供元
- 日付
- 24時間以内 0
- 48時間以内 0
- 72時間以内 0
- 7日以内 0
- 30日以内 0
- 1年以内 1
- 期間を指定 151
- 日付指定なし 151
- 種類
- 写真 139
- グラフィックス 12
- 映像 0
- 向き
- 縦 10
- 横 125
- 正方形 0
- カテゴリ
- ニュース
- スポーツ
- エンターテインメント
- 教育向け
- カテゴリ指定なし
- 色
- カラー 141
- モノクロ 6
- 古い順
- 1
- 2
- 古い順
2020年02月05日新型肺炎の抗ウイルス薬レムデシビル、武漢で臨床試験開始へ５日、プロジェクトの状況を説明する中国工程院副院長で中国医学科学院院長の王辰（おう・しん）院士（右から１人目）。中国科学技術部、国家衛生健康委員会、国家薬品監督管局などの多くの部門の支持の下、抗ウイルス薬物「レムデシビル（ｒｅｍｄｅｓｉｖｉｒ）」はすでに臨床試験の登録審査・認可の作業を終え、第１陣の症例登録もすでに始まった。新型コロナウイルス感染による肺炎の重症患者に６日に投薬される。（武漢＝新華社記者／程敏）＝２０２０（令和２）年２月５日、クレジット：新華社／共同通信イメージズ
商品コード: 2020020609649
2020年02月05日新型肺炎の抗ウイルス薬レムデシビル、武漢で臨床試験開始へ５日、レムデシビル臨床試験プロジェクトの内容を説明する同プロジェクト責任者で中日友好病院副院長の曹彬（そう・ひん）教授。中国科学技術部、国家衛生健康委員会、国家薬品監督管局などの多くの部門の支持の下、抗ウイルス薬物「レムデシビル（ｒｅｍｄｅｓｉｖｉｒ）」はすでに臨床試験の登録審査・認可の作業を終え、第１陣の症例登録もすでに始まった。新型コロナウイルス感染による肺炎の重症患者に６日に投薬される。（武漢＝新華社記者／程敏）＝２０２０（令和２）年２月５日、クレジット：新華社／共同通信イメージズ
商品コード: 2020020609687
2020年03月11日World News - March 11, 2020March 11, 2020: A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States in this March 2020 photo provided by Gilead Sciences. (Credit Image: © Ho/The Canadian Press via ZUMA Press)、クレジット：©Ｈｏ／Ｔｈｅ Ｃａｎａｄｉａｎ Ｐｒｅｓｓ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｃａｎａｄａ ａｎｄ Ｕ．Ｓ． ＲＩＧＨＴＳ ＯＵＴ
商品コード: 2020073104134
2020年03月11日World News - March 11, 2020March 11, 2020: A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States in this March 2020 photo provided by Gilead Sciences. Health Canada has approved the use of remdesivir to treat patients with severe symptoms of COVID-19. The federal agency says the antiviral drug may be used to treat patients who have pneumonia and require extra oxygen to help them breathe. (Credit Image: © Ho/The Canadian Press via ZUMA Press)、クレジット：©Ｈｏ／Ｔｈｅ Ｃａｎａｄｉａｎ Ｐｒｅｓｓ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ／共同通信イメージズ ※Ｃａｎａｄａ ａｎｄ Ｕ．Ｓ． ＲＩＧＨＴＳ ＯＵＴ
商品コード: 2020073100862
2020年03月19日抗ＨＩＶ薬、ぜんそく薬…新型コロナウイルス感染症に効果が期待される既存薬
商品コード: 2020031922672
2020年03月19日抗ＨＩＶ薬、ぜんそく薬…新型コロナウイルス感染症に効果が期待される既存薬
商品コード: 2020031922675
2020年03月24日Martin BalikDoctor Martin Balik of the General Teaching Hospital in Prague speaks during a press conference on coronavirus treatment, on March 24, 2020, in Prague, Czech Republic. The hospital received the remdesivir novel antiviral drug and it started administering it to a patient seriously ill with COVID-19. (CTK Photo/Ondrej Deml)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020032513223
2020年03月24日David FeltlDirector of the General Teaching Hospital in Prague David Feltl speaks during a press conference on coronavirus treatment, on March 24, 2020, in Prague, Czech Republic. The hospital received the remdesivir novel antiviral drug and it started administering it to a patient seriously ill with COVID-19. (CTK Photo/Ondrej Deml)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020032513261
2020年03月24日Martin Balik, David FeltlDoctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 24, 2020, in Prague, Czech Republic. The hospital received the remdesivir novel antiviral drug and it started administering it to a patient seriously ill with COVID-19. (CTK Photo/Ondrej Deml)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020032512896
2020年03月27日Martin BalikDoctor Martin Balik of the General Teaching Hospital in Prague speaks during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020033105172
2020年03月27日Martin Balik, David FeltlDoctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020033105152
2020年03月27日Martin Balik, David FeltlDoctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020033105163
2020年03月27日Martin Balik, David FeltlDoctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020033105158
2020年03月27日Martin Balik, David FeltlDoctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020033105159
2020年03月27日Martin Balik, David FeltlDoctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020033105157
2020年03月27日David FeltlDirector of the General Teaching Hospital in Prague David Feltl speaks during a press conference on coronavirus treatment, on March 27, 2020, in Prague, Czech Republic. The condition of a Czech COVID-19 patient has markedly improved after the U.S. remdesivir experimental medicine was administered to him for three days. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020033105167
2020年04月03日Martin Balik, David FeltlThe General Teaching Hospital in Prague (VFN) completed the treatment of a COVID-19 patient, 53, with the Remdesivir experimental drug, the only patient treated with the drug in the Czech Republic so far, the VFN Anaesthesiology Clinic deputy head Martin Balik, left, and VFN director David Feltl reported today, on Friday, April 3, 2020, in Prague, Czech Republic. (CTK Photo/Katerina Sulova)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020040800420
2020年04月03日Martin Balik, David FeltlThe General Teaching Hospital in Prague (VFN) completed the treatment of a COVID-19 patient, 53, with the Remdesivir experimental drug, the only patient treated with the drug in the Czech Republic so far, the VFN Anaesthesiology Clinic deputy head Martin Balik, left, and VFN director David Feltl reported today, on Friday, April 3, 2020, in Prague, Czech Republic. (CTK Photo/Katerina Sulova)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020040800379
2020年04月03日Martin Balik, David FeltlThe General Teaching Hospital in Prague (VFN) completed the treatment of a COVID-19 patient, 53, with the Remdesivir experimental drug, the only patient treated with the drug in the Czech Republic so far, the VFN Anaesthesiology Clinic deputy head Martin Balik, left, and VFN director David Feltl reported today, on Friday, April 3, 2020, in Prague, Czech Republic. (CTK Photo/Katerina Sulova)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020040800409
2020年04月03日Martin Balik, David FeltlThe General Teaching Hospital in Prague (VFN) completed the treatment of a COVID-19 patient, 53, with the Remdesivir experimental drug, the only patient treated with the drug in the Czech Republic so far, the VFN Anaesthesiology Clinic deputy head Martin Balik, left, and VFN director David Feltl reported today, on Friday, April 3, 2020, in Prague, Czech Republic. (CTK Photo/Katerina Sulova)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020040800373
2020年04月08日Coronavirus - Study start at the UKE with Ebola drug Remdesivir08 April 2020, Hamburg: An ampoule of the drug Remdesivir is on the table during a press conference at the University Hospital Eppendorf (UKE). The hospital management informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020041000960
2020年04月08日Coronavirus - Study start at the UKE with Ebola drug Remdesivir08 April 2020, Hamburg: Two ampoules of the drug Remdesivir are on the table during a press conference at the University Hospital Eppendorf (UKE). The hospital management informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020041000961
2020年04月08日Coronavirus - Study start at the UKE with Ebola drug Remdesivir08 April 2020, Hamburg: The head of Infectiology, Professor Dr. Marylyn Addo, talks to the journalists during a press conference at the University Hospital Eppendorf (UKE). The hospital informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020041000971
2020年04月08日Corona drug RemdesivirFILED - 08 April 2020, Hamburg: An ampoule of the drug Remdesivir is on the table during a press conference at the University Hospital Eppendorf (UKE). The EU Commission has concluded a supply contract with the manufacturer Gilead to supply 30,000 seriously ill Covid-19 patients with the drug Remdesivir. The active ingredient - the only drug approved in Europe to date for severe cases of coronavirus-induced lung disease - will be supplied from the beginning of August, the Brussels authorities announced on Wednesday. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020073105809
2020年04月08日Coronavirus - Study start at the UKE with Ebola drug Remdesivir08 April 2020, Hamburg: The head of Infectiology, Professor Dr. Marylyn Addo, holds ampoules of the drug Remdesivir in her hands during a press conference at the University Hospital Eppendorf (UKE). The hospital informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020041000967
2020年04月08日Coronavirus - Study start at the UKE with Ebola drug Remdesivir08 April 2020, Hamburg: The head of the Institute for Transfusion Medicine, Dr. Sven Peine, answers the questions of the journalists during a press conference at the University Hospital Eppendorf (UKE). The hospital management informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020041001022
2020年04月08日Coronavirus - Study start at the UKE with Ebola drug Remdesivir08 April 2020, Hamburg: The director of the Department of Intensive Care Medicine, Prof. Dr. Stefan Kluge (l-r), the head of Infectiology, Prof. Dr. Marylyn Addo, and the head of the Institute of Transfusion Medicine, Dr. Sven Peine, answered the journalists‘ questions during a press conference at the University Hospital Eppendorf (UKE). They informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020041000945
2020年04月08日Coronavirus - Study start at the UKE with Ebola drug Remdesivir08 April 2020, Hamburg: An ampoule of the drug Remdesivir is lying on one hand during a press conference at the University Hospital Eppendorf (UKE). The hospital management informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020041000985
2020年04月08日Coronavirus - Study start at the UKE with Ebola drug Remdesivir08 April 2020, Hamburg: The director of the Department of Intensive Care Medicine, Prof. Dr. Stefan Kluge (l-r), the head of Infectiology, Prof. Dr. Marylyn Addo, and the head of the Institute of Transfusion Medicine, Dr. Sven Peine, answered the journalists‘ questions during a press conference at the University Hospital Eppendorf (UKE). They informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020041000998
2020年04月08日Coronavirus - Study start at the UKE with Ebola drug Remdesivir08 April 2020, Hamburg: The head of Infectiology, Professor Dr. Marylyn Addo, talks to the journalists during a press conference at the University Hospital Eppendorf (UKE). The hospital informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020041001003
2020年04月08日Coronavirus - Study start at the UKE with Ebola drug Remdesivir08 April 2020, Hamburg: The director of the Department of Intensive Care Medicine, Prof. Dr. Stefan Kluge, will answer the journalists‘ questions during a press conference at the University Hospital Eppendorf (UKE). The hospital management informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020041001016
2020年04月08日Coronavirus - Study start at the UKE with Ebola drug Remdesivirdpatop - 08 April 2020, Hamburg: An ampoule of the drug Remdesivir is on the table during a press conference at the University Hospital Eppendorf (UKE). The hospital management informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020041001101
2020年04月08日Coronavirus - Study start at the UKE with Ebola drug Remdesivir08 April 2020, Hamburg: The head of Infectiology, Professor Dr. Marylyn Addo, talks to the journalists during a press conference at the University Hospital Eppendorf (UKE). The hospital informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020041001001
2020年04月08日Coronavirus - Study start at the UKE with Ebola drug Remdesivir08 April 2020, Hamburg: The head of Infectiology, Professor Dr. Marylyn Addo, talks to the journalists during a press conference at the University Hospital Eppendorf (UKE). The hospital informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020041000964
2020年04月08日Coronavirus - Study start at the UKE with Ebola drug Remdesivir08 April 2020, Hamburg: Two ampoules of the drug Remdesivir are on the table during a press conference at the University Hospital Eppendorf (UKE). The hospital management informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo: Ulrich Perrey/dpa-POOL/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020041000980
2020年04月10日レムデシビル 進む既存薬試験、新薬開発エボラ出血熱の治療薬候補「レムデシビル」（ロイター＝共同）
商品コード: 2020041002488
2020年04月11日レムデシビル エボラ薬「見込みあり」新型コロナウイルス感染症の治療に期待されている抗ウイルス薬「レムデシビル」（ロイター＝共同）
商品コード: 2020041101360
2020年04月30日レムデシビル コロナ薬効果、米中で違い新型コロナウイルス感染症の治療薬候補「レムデシビル」（ロイター＝共同）
商品コード: 2020043000066
2020年05月02日トランプ大統領 米、レムデシビル投与許可ホワイトハウスの執務室で「レムデシビル」を開発した米製薬企業ギリアド・サイエンシズの幹部と面会するトランプ米大統領（右）＝１日（ゲッティ＝共同）
商品コード: 2020050200084
2020年05月02日レムデシビル 早期承認に向け閣議決定米製薬会社ギリアド・サイエンシズが開発した新型コロナウイルス感染症の治療候補薬レムデシビル（ロイター＝共同）
商品コード: 2020050200393
2020年05月02日厚労相「１週間で承認」商品コード: 2020050200409-3
2020年05月02日厚労相「１週間で承認」商品コード: 2020050200409-1
2020年05月02日厚労相「１週間で承認」商品コード: 2020050200409-4
2020年05月02日厚労相「１週間で承認」商品コード: 2020050200409-2
2020年05月02日取材に応じる加藤厚労相 厚労相「１週間で承認」新型コロナウイルスの治療候補薬レムデシビルの特例承認について話す加藤厚労相＝２日午後、厚労省
商品コード: 2020050200409
2020年05月02日取材に応じる加藤厚労相 厚労相「１週間で承認」新型コロナウイルスの治療候補薬レムデシビルの特例承認について話す加藤厚労相＝２日午後、厚労省
商品コード: 2020050200408
2020年05月05日Robert Markovic, David FeltlThe General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (left), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. On the right side is seen director of the hospital David Feltl. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020051101491
2020年05月05日Robert MarkovicThe General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (photo), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020051101499
2020年05月05日Robert MarkovicThe General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (photo), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020051101501
2020年05月05日Robert MarkovicThe General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (photo), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020051101384
2020年05月05日Robert MarkovicThe General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (photo), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020051101393
2020年05月05日Robert MarkovicThe General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (photo), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020051101394
2020年05月05日Robert MarkovicThe General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (photo), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020051101415
2020年05月05日Robert Markovic, Michal SotolaThe General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (left), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. On the right side is seen doctor Michal Sotola. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020051101398
2020年05月05日Robert MarkovicThe General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (photo), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020051101409
2020年05月05日Robert Markovic, Martin BalikThe General Teaching Hospital (VFN) in Prague released to home care Robert Markovic (left), the man who has been the first patient with COVID 19 treated by the remdesivir experimental drug in Czechia, today, on Tueday, May 5, 2020. The 53-year-old taxi driver was hospitalised with a severe course of the COVID-19 disease on March 10. He received remdesivir intravenously for ten days at the end of March and the beginning of April. On the right side is seen doctor Martin Balik. (CTK Photo/Michal Krumphanzl)、クレジット：ＣＴＫ／共同通信イメージズ
商品コード: 2020051101507
2020年05月07日レムデシビル コロナ治療薬、初承認へ米製薬企業が開発した「レムデシビル」（ロイター＝共同）
商品コード: 2020050700914
2020年05月07日コロナ治療に多数の候補薬新型コロナウイルス感染症の治療法として注目される薬の例
商品コード: 2020050701279
2020年05月07日コロナ治療に多数の候補薬新型コロナウイルス感染症の治療法として注目される薬の例
商品コード: 2020050701278
2020年05月07日コロナ治療に多数の候補薬新型コロナウイルス感染症の治療法として注目される薬の例
商品コード: 2020050701281
2020年05月07日コロナ治療に多数の候補薬新型コロナウイルス感染症の治療法として注目される薬の例
商品コード: 2020050701283
2020年05月07日取材に応じる加藤厚労相 コロナ治療薬、国が初承認新型コロナウイルス感染症の治療薬として「レムデシビル」を国内で初めて承認し、取材に応じる加藤厚労相＝７日午後９時５９分、厚労省
商品コード: 2020050702285
2020年05月07日レムデシビルの使用法レムデシビルの主な使用法や注意点
商品コード: 2020050702329
2020年05月07日レムデシビルの使用法レムデシビルの主な使用法や注意点
商品コード: 2020050702332
2020年05月07日レムデシビルの使用法レムデシビルの主な使用法や注意点
商品コード: 2020050702334
2020年05月07日レムデシビルの使用法レムデシビルの主な使用法や注意点
商品コード: 2020050702336
2020年05月07日発表する加藤厚労相 コロナ治療薬、国が初承認新型コロナウイルス感染症の治療薬として「レムデシビル」を国内で初めて承認したことを発表する加藤厚労相＝７日午後９時５９分、厚労省
商品コード: 2020050702342
2020年05月07日質問に答える加藤厚労相 コロナ治療薬、国が初承認新型コロナウイルス感染症の治療薬として「レムデシビル」を国内で初めて承認したことを発表し、取材に応じる加藤厚労相（中央）＝７日午後１０時２分、厚労省
商品コード: 2020050702347
2020年05月07日応じる加藤厚労相 コロナ治療薬、国が初承認新型コロナウイルス感染症の治療薬として「レムデシビル」を国内で初めて承認したことを発表し、取材に応じる加藤厚労相＝７日午後１０時５分、厚労省
商品コード: 2020050702370
2020年05月07日答える加藤厚労相 コロナ治療薬、国が初承認新型コロナウイルス感染症の治療薬として「レムデシビル」を国内で初めて承認したことを発表し、取材に応じる加藤厚労相＝７日午後１０時５分、厚労省
商品コード: 2020050702378
2020年05月07日取材対応する加藤厚労相 コロナ治療薬、国が初承認新型コロナウイルス感染症の治療薬として「レムデシビル」を国内で初めて承認したことを発表し、取材に応じる加藤厚労相（中央奥）＝７日午後１０時２分、厚労省
商品コード: 2020050702490
2020年05月08日国内初のコロナ治療薬レムデシビルの特徴
商品コード: 2020050805580
2020年05月08日国内初のコロナ治療薬レムデシビルの特徴
商品コード: 2020050805581
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107213
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107255
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: Samples for coronavirus research are placed on a table in the laboratory of the Heinrich Heine University in Düsseldorf. The research projects include immunity after cured infection and research data on the effectiveness and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107256
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107370
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107244
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107233
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107279
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107317
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107337
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A sign with the inscription “Genlabor S2“ sticks to a door. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107428
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107091
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107125
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107165
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107219
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: Samples for coronavirus research are placed on a table in the laboratory of the Heinrich Heine University in Düsseldorf. The research projects include immunity after cured infection and research data on the effectiveness and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107220
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107297
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107344
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107398
2020年05月20日Coronavirus - Research in Düsseldorf20 May 2020, North Rhine-Westphalia, Duesseldorf: A doctoral student at the Heinrich Heine University in Düsseldorf is working on samples for coronavirus research. The research projects include immunity after cured infection and research data on the efficacy and significance of Remdesivir in clinical application. Photo: Marcel Kusch/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020052107135
2020年05月29日On remdesivir import On remdesivir importOn remdesivir import Jung Eun-kyeong, head of the Korea Centers for Disease Control and Prevention (KCDC), listens to a reporter‘s question about a plan to import U.S. pharmaceutical giant Gilead Sciences Inc.‘s remdesivir as special treatment for COVID-19 patients during a regular briefing session at the KCDC headquarters in Cheongju, 137 kilometers south of Seoul, on May 29, 2020. (Yonhap)/2020-05-29 17:13:01/ ＜ 1980-2020 YONHAPNEWS AGENCY. .＞ (Newscom TagID: yonphotos168300) [Photo via Newscom]、クレジット：ＹＯＮＨＡＰＮＥＷＳ／ニューズコム／共同通信イメージズ
商品コード: 2020060803401
2020年06月03日Seoul approves remdesivir as virus treatment Seoul approves remdesivir as virus treatmentSeoul approves remdesivir as virus treatment A medical worker checks bottles of the anti-viral drug remdesivir for patients infected with the new coronavirus at Seoul National University Hospital on June 3, 2020. South Korea the same day approved the use of the drug, developed by U.S. firm Gilead Sciences Inc., paving the way for the first inbound shipments of the new drug. (Yonhap)/2020-06-03 16:14:21/ ＜ 1980-2020 YONHAPNEWS AGENCY. .＞ (Newscom TagID: yonphotos168598) [Photo via Newscom]、クレジット：ＹＯＮＨＡＰＮＥＷＳ／ニューズコム／共同通信イメージズ
商品コード: 2020061801874
2020年06月29日COVID-19 medicine production in Egypt29 June 2020, Egypt, Giza: An employee of Egyptian pharmaceutical company Eva Pharma works on the production line of Remdesivir, a broad-spectrum antiviral medication which has been approved as a specific treatment for COVID-19. Eva Pharma started this week the production of Remdesivir with a production capacity of up to 1.5 million doses per month. Photo: Fadel Dawood/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020063005185
2020年06月29日COVID-19 medicine production in Egypt29 June 2020, Egypt, Giza: An employee of Egyptian pharmaceutical company Eva Pharma holds a pack containing vials of Remdesivir, a broad-spectrum antiviral medication approved as a specific treatment for COVID-19, at the company‘s factory, which started producing the drug this week with a production capacity of up to 1.5 million doses per month. Photo: Fadel Dawood/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020063005264
2020年06月29日COVID-19 medicine production in Egypt29 June 2020, Egypt, Giza: Employees of Egyptian pharmaceutical company Eva Pharma operate at the company‘s factory, where the production of Remdesivir, a broad-spectrum antiviral medication approved as a specific treatment for COVID-19, has started this week with a production capacity of up to 1.5 million doses per month. Photo: Fadel Dawood/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020063005322
2020年06月29日COVID-19 medicine production in Egypt29 June 2020, Egypt, Giza: Employees of Egyptian pharmaceutical company Eva Pharma operate at the company‘s factory, where the production of Remdesivir, a broad-spectrum antiviral medication approved as a specific treatment for COVID-19, has started this week with a production capacity of up to 1.5 million doses per month. Photo: Fadel Dawood/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020063005459
2020年06月29日COVID-19 medicine production in Egypt29 June 2020, Egypt, Giza: An employee of Egyptian pharmaceutical company Eva Pharma works on the production line of Remdesivir, a broad-spectrum antiviral medication which has been approved as a specific treatment for COVID-19. Eva Pharma started this week the production of Remdesivir with a production capacity of up to 1.5 million doses per month. Photo: Fadel Dawood/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020063005196
2020年06月29日COVID-19 medicine production in Egypt29 June 2020, Egypt, Giza: Packs containing vials of Remdesivir, a broad-spectrum antiviral medication approved as a specific treatment for COVID-19, lie next to an employee of Egyptian pharmaceutical company Eva Pharma at the company‘s factory, which started producing the drug this week with a production capacity of up to 1.5 million doses per month. Photo: Fadel Dawood/dpa、クレジット：ＤＰＡ／共同通信イメージズ
商品コード: 2020063005255
- 1
- 2
